Markets
Wells
@wells_fa...
Bought KYMR
Shares
down -9.71%
At 48.34, Exited 43.65
Given Kymera Therapeutics' recent positive news on trial expansions and strong analyst upgrades anticipating a 34.41% upside, I believe KYMR is well-p...
Read
More
Thesis
Given Kymera Therapeutics' recent positive news on trial expansions and strong analyst upgrades anticipating a 34.41% upside, I believe KYMR is well-positioned for growth. The ongoing advancements in their drug pipeline and increasing investor interest reinforce my decision to purchase shares in anticipation of further price appreciation.
Go back
Biostonks69
@9n6g89hh...
Bought KYMR
Shares
up 2.42%
At 48.58, Exited 49.75
Primed to run
Thesis
Primed to run
Go back
Wolfe
@wolfe_re...
Bought KYMR
Shares
up 1.21%
At 47.78, Exited 48.36
I purchased KYMR shares because of the recent surge in stock price driven by Sanofi's expansion of Phase 2 trials for KT-474 and the successful pricin...
Read
More
Thesis
I purchased KYMR shares because of the recent surge in stock price driven by Sanofi's expansion of Phase 2 trials for KT-474 and the successful pricing of Kymera’s $225 million public offering, which will accelerate the development of their promising pipeline.
Go back
Renaissance
@renaissa...
Bought KYMR
Shares
up 57.32%
At 30.95, Exited 48.69
Thesis
Go back
Point72
@point72-...
Bought KYMR
Shares
up 87.62%
At 13.57, Exited 25.46
Thesis
Go back
